Amphastar Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Amphastar Pharmaceuticals es Jack Zhang , nombrado en Jan 1996, tiene una permanencia de 28.83 años. compensación anual total es $7.72M, compuesta por 11.6% salario y 88.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.01% de las acciones de la empresa, por valor de $125.70M. La antigüedad media del equipo directivo y de la junta directiva es de 11 años y 5.4 años, respectivamente.
Información clave
Jack Zhang
Chief Executive Officer (CEO)
US$7.7m
Compensación total
| Porcentaje del salario del CEO | 11.6% |
| Permanencia del CEO | 28.8yrs |
| Participación del CEO | 5.0% |
| Permanencia media de la dirección | 11yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
Compensación vs. Mercado: La compensación total ($USD7.72M) de Jack está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.64M).
Compensación vs. Ingresos: La compensación de Jack ha sido consistente con los resultados de la empresa en el último año.
CEO
Jack Zhang (77 yo)
28.8yrs
Permanencia
US$7,722,768
Compensación
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 28.8yrs | US$3.77m | 2.36% $ 59.1m | |
| Co-founder | 28.8yrs | US$7.72m | 5.01% $ 125.7m | |
| CFO, Executive VP of Finance | 10.6yrs | US$2.89m | 0.075% $ 1.9m | |
| Executive VP of Sales | 11.4yrs | US$1.78m | 0.096% $ 2.4m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9.4yrs | US$2.03m | 0.38% $ 9.6m | |
| Senior Vice President of Human Resources & Corporate Communication | 2.3yrs | sin datos | sin datos | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | sin datos | sin datos |
11.0yrs
Permanencia media
65yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AMPH es experimentado (11 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 28.8yrs | US$3.77m | 2.36% $ 59.1m | |
| Co-founder | 28.8yrs | US$7.72m | 5.01% $ 125.7m | |
| CFO, Executive VP of Finance | 2.3yrs | US$2.89m | 0.075% $ 1.9m | |
| Executive VP of Sales | 2.3yrs | US$1.78m | 0.096% $ 2.4m | |
| Lead Independent Director | 22.8yrs | US$362.00k | 0.063% $ 1.6m | |
| Independent Director | 3.4yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.4yrs | US$314.70k | 0.026% $ 662.1k |
5.4yrs
Permanencia media
65.5yo
Promedio de edad
Junta con experiencia: La junta directiva de AMPH se considera experimentada (5.4 años de antigüedad promedio).